Omeros Corporation
omeros.comWhat Do They Do?
Sells YARTEMLEA, a treatment for a transplant complication, to transplant centers and develops medicines for complement-related diseases.
10-K for FY2025, filed Mar 31, 2026YARTEMLEA® (narsoplimab-wuug) is the first and only approved therapy for hematopoietic stem cell transplant-associated thrombotic…View ↗
MASP-2, a novel pro-inflammatory protein target, is the effector enzyme of the lectin pathway and is required for the function of this…View ↗
We are commercializing YARTEMLEA in the U.S. market and have deployed a field force of account managers and directors, market development…View ↗
Who Are Their Customers?
Omeros’s U.S. team engages directly with transplant centers about YARTEMLEA and works with third-party payers on reimbursement. For sales outside the U.S., it is evaluating broader or regional partnerships.
10-K for FY2025, filed Mar 31, 2026We are commercializing YARTEMLEA in the U.S. market and have deployed a field force of account managers and directors, market development…View ↗
At this early stage, our primary launch objectives are fourfold: (i) educate the entire transplant care team, including transplant…View ↗
For commercialization of YARTEMLEA outside the U.S., we are evaluating potential partnerships, both broad ex-U.S. arrangements and regional…View ↗
How Are They Changing?
From development to sales
Earlier, narsoplimab was still under development and its approval was unresolved; the latest report describes YARTEMLEA as an approved, commercially sold treatment for a complication of stem-cell transplantation.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Mar 31, 2026
Zaltenibart rights transferred
Zaltenibart moved from Omeros’s clinical pipeline to Novo Nordisk’s development and commercialization rights; Omeros retained its unrelated small-molecule program.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Mar 31, 2026Our pipeline of clinical-stage complement-targeted therapeutic candidates also includes OMS906, a proprietary, patented monoclonal antibody…View ↗
Loading...
